SCHEDULE 13G/A: Wellington Management Entities Disclose 8.4% Stake in Charles River Laboratories

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% of Charles River Laboratories International, Inc. common stock as of March 31, 2025.

Summary

• Wellington Management Group LLP, along with Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively reported beneficial ownership of 4,285,012 shares of Charles River Laboratories International, Inc. common stock.
• This represents 8.4% of the class of securities, as of the reporting date of March 31, 2025.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously filed ownership statement.
• The reporting persons certified that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• The beneficial ownership includes shared voting power over 3,871,306 shares and shared dispositive power over 4,285,012 shares for the primary reporting entities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The document is a routine ownership disclosure, which is generally neutral. The continued significant stake by a major institutional investor like Wellington Management can be seen as a positive signal of confidence, but it provides no new operational or financial insights into the company itself.

Positives

• A significant institutional investor, Wellington Management, maintains a substantial stake (8.4%) in Charles River Laboratories, which can be interpreted as a sign of continued confidence in the company.
• The filing explicitly states the shares are held in the ordinary course of business and not for control purposes, suggesting a passive investment strategy that avoids potential activist disruptions.

Future Outlook

The document is a Schedule 13G filing, which reports beneficial ownership by an institutional investor and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.

Management Comments

• The document does not contain direct quotes or paraphrased statements from Charles River Laboratories International, Inc. management. It includes certifications from Wellington Management Group LLP's Regulatory Analyst, Taisia Lowe, stating the securities were acquired and held in the ordinary course of business and not for control purposes.

Industry Context

This filing reflects a routine disclosure of a significant passive investment by a major asset manager in a publicly traded company within the life sciences or pharmaceutical services industry. It indicates continued institutional interest in Charles River Laboratories International, Inc. but does not provide broader industry trend analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Wellington Management may provide a degree of confidence to other shareholders, signaling continued institutional interest.
• Employees, Customers, Suppliers, Creditors: This filing is an ownership disclosure and does not directly impact these stakeholders' day-to-day operations or relationships with Charles River Laboratories International, Inc.

Key Dates

Recommendation

Keywords

Charles River Laboratories, CRL, Wellington Management, Schedule 13G, Institutional Ownership, Common Stock, SEC Filing, Beneficial Ownership, Investment Management